Organogenesis Holdings INC 8-K filings

Organogenesis Holdings Inc. has entered into an At-the-Market Sales Agreement to potentially sell up to $75 million of its Class A common stock.

Organogenesis Holdings Inc. held its 2026 Annual Meeting of Stockholders, approving key proposals including director elections and auditor ratification.

Organogenesis Holdings Inc. announced record net product revenue for fiscal year 2025, reaching $563.0 million, despite anticipating a challenging first half of 2026 due to CMS payment reforms.

Organogenesis Holdings Inc. announced the appointment of Patrick McGuire as its new Chief Accounting Officer, effective February 18, 2026.

Organogenesis Holdings Inc. has extended leases for its critical Canton, MA manufacturing and R&D facilities, securing operations through at least 2032 with an option to 2034.

Organogenesis Holdings Inc. reported record third-quarter 2025 financial results, driven by strong product revenue growth, and subsequently raised its full-year 2025 guidance.

Organogenesis Holdings Inc. announced its second Phase 3 trial for ReNu, a knee osteoarthritis treatment, did not achieve statistical significance for its primary pain reduction endpoint, despite numerical improvement.

Organogenesis Holdings Inc. reported a significant decline in Q2 2025 net product revenue and adjusted EBITDA, while also amending its credit agreement to waive a covenant test for the quarter and requiring new financial covenants by September 30, 2025.

Organogenesis Holdings Inc. announced that its stockholders approved all four proposals at the 2025 Annual Meeting, including the election of directors, advisory approval of executive compensation, and the conversion of Series A Convertible Preferred Stock.

Organogenesis Holdings Inc. reported a decrease in net revenue and a significant increase in net loss for the first quarter of 2025, while reaffirming its annual revenue guidance.

Organogenesis Holdings Inc. released an investor presentation on March 27, 2025, outlining its growth strategy, regenerative medicine innovations, and clinical pipeline, including the ReNu osteoarthritis treatment.

Organogenesis Holdings Inc. announced a significant increase in net revenue and income for Q4 2024 and fiscal year 2024, driven by growth in both Advanced Wound Care and Surgical & Sports Medicine product lines, and anticipates submitting the ReNu BLA by the end of 2025.

Organogenesis Holdings Inc. has agreed to repurchase 500,000 shares of its Class A common stock from the GN 2016 Family Trust for $2,028,500.

Organogenesis Holdings Inc. has entered into a long-term lease for a 122,000-square-foot biomanufacturing facility in Smithfield, Rhode Island, to support future growth.

Organogenesis Holdings Inc. has successfully raised $130 million through a private placement of Series A Convertible Preferred Stock to fund strategic growth initiatives and repurchase shares from existing stockholders.

Organogenesis Holdings Inc. announced a 6% increase in net revenue and a significant rise in net income for the third quarter of 2024, driven by growth in its Advanced Wound Care product line.

Organogenesis Holdings Inc. reported a revenue increase of 11% year-over-year for the second quarter of 2024, but experienced a net loss due to higher operating expenses.

Organogenesis Holdings Inc. stockholders approved an amendment to the 2018 Equity Incentive Plan, increasing the number of shares reserved for issuance by 15.9 million, and elected eleven directors at the 2024 Annual Meeting.

Organogenesis Holdings Inc. announced its first quarter 2024 financial results, showing a slight revenue increase but a decrease in adjusted EBITDA, while reaffirming its full-year 2024 guidance.

Organogenesis Holdings Inc. announced that a U.S. District Court dismissed all claims in a securities fraud case against the company and its executives.

Organogenesis Holdings Inc. reported a decrease in revenue and profitability for both the fourth quarter and full year 2023, but anticipates a return to growth in 2024.